Strategy For Treatment Of Krabbe's Disease, A Fatal Nervous System Disorder
Working with mice, University of
Wisconsin-Madison researchers have developed the basis for a therapeutic
strategy that could provide hope for children afflicted with Krabbe's disease, a
fatal nervous system disorder.
Writing this week (Dec. 12, 2005) in the Proceedings of the National Academy of
Sciences (PNAS), a team of researchers at the UW-Madison School of Veterinary
Medicine describes experiments that effectively promoted the ability of
defective cells to take up and utilize an enzyme that is essential for the
maintenance of a critical sheathing of nerve fibers.
The work centers on devising strategies to treat inherited diseases of the
nervous system in which cells fail to maintain myelin, a protective sheathing
that envelops nerve fibers and acts like the insulation on an electric wire.
Myelin ensures the effective transmission of the signals routinely conducted by
the nervous system. For those afflicted with Krabbe's disease, the loss of
myelin results in arrested motor and mental development, seizures, paralysis
and, ultimately, death.
The Wisconsin experiments, led by Ian Duncan, a UW-Madison professor of medical
sciences who is an expert on diseases of myelin, explored how cells obtained
from a mouse model of Krabbe's disease could be reinvigorated by replacing a
missing enzyme, and thus allow the healthy maintenance of myelin. In the case of
Krabbe's disease, myelination begins normally in early development. But the
absence in myelin-forming cells of a key enzyme known as galactocerebrosidase
leads to the death of the cells and, subsequently, the loss of myelin.
"Our hypothesis was that if you provided the (flawed) myelinating cells with the
enzyme, the cells would maintain the myelin as healthy cells would," says
Duncan, the senior author of the PNAS paper who planned and conducted the
experiments with lead author Yoichi Kondo, a postdoctoral fellow working in
Duncan's lab.
Simply supplying the enzyme directly to the brain and spinal cord is complicated
by a natural barrier -- the blood-brain barrier -- that makes the delivery of
agents like the enzyme to the brain difficult.
"To eliminate the barrier, we changed the paradigm by transplanting
enzyme-deficient cells into the brain and spinal cord of another type of mouse
which can provide the enzyme," explains Duncan.
The Wisconsin group isolated progenitor cells from the mouse model of Krabbe's
disease. Transplanting the cells to the brain and spinal cord of another type of
mouse that lacks any myelin, the group observed that the implanted cells took up
the enzyme from the host cells and sparked widespread and persistent myelination
of the brain and spinal cord.
"The donor cells are stable and survive and, biochemically, enzyme levels in the
graft were restored to normal," says Kondo.
Enzyme replacement therapy, Duncan notes, is not a new idea for treating such
inherited demyelinating diseases. For example, work by other groups involving
transplants of bone marrow and umbilical cord blood in Krabbe's patients have
been attempted with some success.
But no one knew if the missing enzyme could be replaced in key cells known as
oligodendrocytes, thus allowing maintenance of stable myelin throughout the
nervous system.
"This experimental strategy proves that oligodendrocytes can survive and
maintain myelin when transplanted into an environment where the missing enzyme
is available," says Kondo.
Krabbe's disease is perhaps best known to the public through the efforts of Hall
of Fame quarterback Jim Kelly, whose late son Hunter was afflicted with the
disease and who established a foundation, Hunter's Hope, to promote awareness
and research. The new study was funded by Hunter's Hope.
Krabbe's disease is one of a number of diseases caused by the inability to
produce and maintain myelin. It afflicts about 1 in every 100,000 people and
treatment options are limited at best.
The new work, the authors emphasize, provides proof of principle for a new
therapeutic strategy, but any therapy developed on the group's new insights will
require further study.
In addition to Duncan and Kondo, authors of the PNAS paper include David A.
Wenger of Jefferson Medical College in Philadelphia, and Vittorio Gallo of the
Children's National Medical Center in Washington.
University of Wisconsin-Madison
500 Lincoln Dr., 27 Bascom Hall
Madison, WI 53706
United States
www.news.wisc.edu
![]()